title: Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.
abstract: Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twenty-three of patients (72%) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable--one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (n = 21) is 52 months (30+ - 75+). Median survival and 5-year survival rate of all patients are 36 months and 46%, in R0 patients 68 months and 63% (R0-IIB/IIIA/IIIB: not yet reached and 67%). This multimodality treatment including surgery proved highly effective with 100% local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients.
authors.affiliation: Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School. Wilfried.eberhardt@uni-essen.de
authors.forename: W
authors.initials: W
authors.lastname: Eberhardt
authors.forename: G
authors.initials: G
authors.lastname: Stamatis
authors.forename: M
authors.initials: M
authors.lastname: Stuschke
authors.forename: H
authors.initials: H
authors.lastname: Wilke
authors.forename: M R
authors.initials: MR
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Kolks
authors.forename: M
authors.initials: M
authors.lastname: Flasshove
authors.forename: J
authors.initials: J
authors.lastname: Schütte
authors.forename: M
authors.initials: M
authors.lastname: Stahl
authors.forename: L
authors.initials: L
authors.lastname: Schlenger
authors.forename: V
authors.initials: V
authors.lastname: Budach
authors.forename: D
authors.initials: D
authors.lastname: Greschuchna
authors.forename: G
authors.initials: G
authors.lastname: Stüben
authors.forename: H
authors.initials: H
authors.lastname: Teschler
authors.forename: H
authors.initials: H
authors.lastname: Sack
authors.forename: S
authors.initials: S
authors.lastname: Seeber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000209:etiology; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D018570:Risk Assessment; D015996:Survival Rate; D013908:Thoracotomy; D016896:Treatment Outcome